GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shijiazhuang Yiling Pharmaceutical Co Ltd (SZSE:002603) » Definitions » Beneish M-Score

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Beneish M-Score : -1.81 (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shijiazhuang Yiling Pharmaceutical Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -1.81 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Shijiazhuang Yiling Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SZSE:002603' s Beneish M-Score Range Over the Past 10 Years
Min: -2.85   Med: -2.12   Max: -1.32
Current: -1.81

During the past 13 years, the highest Beneish M-Score of Shijiazhuang Yiling Pharmaceutical Co was -1.32. The lowest was -2.85. And the median was -2.12.


Shijiazhuang Yiling Pharmaceutical Co Beneish M-Score Historical Data

The historical data trend for Shijiazhuang Yiling Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shijiazhuang Yiling Pharmaceutical Co Beneish M-Score Chart

Shijiazhuang Yiling Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.95 -2.85 -2.10 -2.65 -1.81

Shijiazhuang Yiling Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.24 -2.13 -2.06 -1.81 -1.81

Competitive Comparison of Shijiazhuang Yiling Pharmaceutical Co's Beneish M-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Shijiazhuang Yiling Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shijiazhuang Yiling Pharmaceutical Co's Beneish M-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shijiazhuang Yiling Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Shijiazhuang Yiling Pharmaceutical Co's Beneish M-Score falls into.



Shijiazhuang Yiling Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Shijiazhuang Yiling Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.7711+0.528 * 1.2376+0.404 * 0.9785+0.892 * 0.6479+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.2071+4.679 * 0.033959-0.327 * 0.9035
=-1.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Total Receivables was ¥3,115 Mil.
Revenue was 2522.633 + 1743.635 + 1784.117 + 2855.605 = ¥8,906 Mil.
Gross Profit was 1298.572 + 678.874 + 1039.432 + 1635.918 = ¥4,653 Mil.
Total Current Assets was ¥6,656 Mil.
Total Assets was ¥17,128 Mil.
Property, Plant and Equipment(Net PPE) was ¥7,318 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥2,697 Mil.
Total Current Liabilities was ¥4,286 Mil.
Long-Term Debt & Capital Lease Obligation was ¥614 Mil.
Net Income was 303.928 + -406.305 + 152.663 + 403.507 = ¥454 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 117.005 + 10.835 + -535.915 + 280.195 = ¥-128 Mil.
Total Receivables was ¥2,715 Mil.
Revenue was 3934.957 + 4586.986 + 2379.589 + 2844.314 = ¥13,746 Mil.
Gross Profit was 2556.28 + 3062.99 + 1464.41 + 1803.786 = ¥8,887 Mil.
Total Current Assets was ¥8,460 Mil.
Total Assets was ¥18,247 Mil.
Property, Plant and Equipment(Net PPE) was ¥6,353 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥3,449 Mil.
Total Current Liabilities was ¥5,562 Mil.
Long-Term Debt & Capital Lease Obligation was ¥214 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(3115.04 / 8905.99) / (2714.588 / 13745.846)
=0.349769 / 0.197484
=1.7711

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(8887.466 / 13745.846) / (4652.796 / 8905.99)
=0.646556 / 0.522434
=1.2376

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (6656.361 + 7318.455) / 17128.471) / (1 - (8459.997 + 6353.298) / 18246.701)
=0.184118 / 0.188166
=0.9785

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=8905.99 / 13745.846
=0.6479

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 6353.298)) / (0 / (0 + 7318.455))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(2697.082 / 8905.99) / (3448.576 / 13745.846)
=0.302839 / 0.250881
=1.2071

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((613.559 + 4285.574) / 17128.471) / ((214.174 + 5562.442) / 18246.701)
=0.286023 / 0.316584
=0.9035

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(453.793 - 0 - -127.88) / 17128.471
=0.033959

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Shijiazhuang Yiling Pharmaceutical Co has a M-score of -1.81 suggests that the company is unlikely to be a manipulator.


Shijiazhuang Yiling Pharmaceutical Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Shijiazhuang Yiling Pharmaceutical Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Business Description

Traded in Other Exchanges
N/A
Address
No. 7 Tianfu street, Biology and medicine industrial base, Huangcun town, Daxing district, Beijing, CHN
Shijiazhuang Yiling Pharmaceutical Co Ltd is a China-based company engages in the pharmaceutical manufacturing. The company is principally engaged in the research, development, manufacturing, and sales of traditional Chinese pharmaceutical products, especially in the fields of cardiovascular and cerebrovascular diseases, respiratory diseases, tumor, diabetes and related complications. Its products include innovative drug series, chemical drugs, Chinese medicine series, and health products.
Executives
Zhang Qiu Lian Directors, executives
Han Yue Zhi Executives
Zhao Shao Hua Executives
Wang Wei Executives
Gao Xue Dong Supervisors
Wu Yi Ling Director
Gao Xiu Qiang Executives
Wu Xiang Jun Directors, executives
Guo Shuang Geng Director
Wang Hua Securities Affairs Representative
Dai Feng Xiang Directors, executives
Liu Gen Wu Supervisors
Wang Wei Ping Directors, executives
Xu Wei Dong Director
Wu Rui Directors, executives

Shijiazhuang Yiling Pharmaceutical Co (SZSE:002603) Headlines

No Headlines